Incyte Correlations

INCY Stock

USD 75.45 0.65 0.87%

The current 90-days correlation between Incyte and Alnylam Pharmaceuticals is 0.23 (i.e., Modest diversification). The correlation of Incyte is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Incyte Correlation With Market

Weak diversification

The correlation between Incyte and DJI is 0.33 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Incyte and DJI in the same portfolio, assuming nothing else is changed.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.

Moving together with Incyte Stock

0.69	VTRS	Viatris	Pair Corr
0.66	ESPR	Esperion Therapeutics	Pair Corr
0.61	EWTX	Edgewise Therapeutics	Pair Corr
0.68	BHC	Bausch Health Companies	Pair Corr
0.77	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.65	EBS	Emergent Biosolutions	Pair Corr
0.75	WAT	Waters	Pair Corr
0.83	GILD	Gilead Sciences	Pair Corr
0.62	BFRIW	Biofrontera Warrants	Pair Corr
0.75	MNMD	Mind Medicine	Pair Corr
0.83	CPRX	Catalyst Pharmaceuticals	Pair Corr

Moving against Incyte Stock

0.79	ZTS	Zoetis Inc	Pair Corr
0.78	HLN	Haleon plc	Pair Corr
0.78	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.78	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.76	LLY	Eli Lilly Sell-off Trend	Pair Corr
0.73	RDY	Dr Reddys Laboratories	Pair Corr
0.7	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.68	TAK	Takeda Pharmaceutical	Pair Corr
0.33	ELAN	Elanco Animal Health Potential Growth	Pair Corr
0.78	ANRO	Alto Neuroscience,	Pair Corr
0.52	ANEB	Anebulo Pharmaceuticals	Pair Corr
0.5	AMGN	Amgen Inc	Pair Corr
0.41	LTRN	Lantern Pharma	Pair Corr
0.41	CTLT	Catalent	Pair Corr
0.4	TEVA	Teva Pharma Industries Sell-off Trend	Pair Corr
0.36	DRMAW	Dermata Therapeutics	Pair Corr
0.31	CVS	CVS Health Corp Aggressive Push	Pair Corr

Related Correlations Analysis

	ALNY	UTHR	RARE	APLS	BGNE	BMRN	IMGN	RXDX	ARWR	IONS
ALNY		0.03	0.55	-0.27	0.52	0.02	0.0	0.11	0.01	0.09	ALNY
UTHR	0.03		-0.56	-0.38	-0.18	-0.45	0.0	0.54	0.16	-0.37	UTHR
RARE	0.55	-0.56		0.46	0.28	0.61	0.0	-0.66	0.17	0.66	RARE
APLS	-0.27	-0.38	0.46		-0.46	0.82	0.0	-0.84	0.62	0.65	APLS
BGNE	0.52	-0.18	0.28	-0.46		-0.17	0.0	0.31	-0.4	-0.15	BGNE
BMRN	0.02	-0.45	0.61	0.82	-0.17		0.0	-0.72	0.54	0.7	BMRN
IMGN	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	IMGN
RXDX	0.11	0.54	-0.66	-0.84	0.31	-0.72	0.0		-0.33	-0.71	RXDX
ARWR	0.01	0.16	0.17	0.62	-0.4	0.54	0.0	-0.33		0.45	ARWR
IONS	0.09	-0.37	0.66	0.65	-0.15	0.7	0.0	-0.71	0.45		IONS
	ALNY	UTHR	RARE	APLS	BGNE	BMRN	IMGN	RXDX	ARWR	IONS

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

BMRN	+ 0.82	APLS
IONS	+ 0.7	BMRN
IONS	+ 0.66	RARE
IONS	+ 0.65	APLS
ARWR	+ 0.62	APLS
BMRN	+ 0.61	RARE

High negative correlations

RXDX	- 0.84	APLS
RXDX	- 0.72	BMRN
IONS	- 0.71	RXDX
RXDX	- 0.66	RARE
RARE	- 0.56	UTHR
BGNE	- 0.46	APLS

Risk-Adjusted Indicators

There is a big difference between Incyte Stock performing well and Incyte Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Incyte's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
ALNY	1.63	(0.29)	0.00	(0.10)	0.00	0.00	2.85	(3.88)	13.26
UTHR	1.23	0.01	0.00	0.12	1.84	(1.17)	2.89	(3.07)	9.81
RARE	1.51	(0.34)	0.00	(0.40)	0.00	0.00	2.65	(3.20)	8.73
APLS	2.51	(0.25)	0.00	(0.26)	0.00	0.00	4.48	(5.17)	15.97
BGNE	1.84	0.16	0.01	(0.63)	2.42	(1.92)	3.97	(4.40)	13.85
BMRN	1.28	(0.52)	0.00	(1.04)	0.00	0.00	1.42	(3.32)	18.88
IMGN	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
RXDX	2.40	1.04	0.50	(11.84)	0.76	(2.61)	2.76	(3.26)	70.71
ARWR	2.77	0.25	0.03	(1.50)	3.15	(3.19)	6.14	(3.86)	19.44
IONS	1.81	(0.33)	0.00	0.57	0.00	0.00	3.09	(3.99)	15.36

Incyte Corporate Management

Sheila JD	General VP	Profile
Thomas Tray	Chief Finance	Profile
Pamela Murphy	Vice Communications	Profile
Paula Swain	Executive Resources	Profile
Christine Chiou	Head Relations	Profile
Michael Morrissey	Executive Operations	Profile
PharmD MBA	Executive America	Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC